New THC strain announcement by WeGROW, promising new development of a Cannabidol-centric strain, will be of great interest to patients, medical providers and cultivators worldwide.
The first strain stemming from the Company’s strategic partnership with leading genetics provider in the UK to exclusively develop unique DNA in Lesotho through breeding, growing, phenotyping and processing. The award-winning genetics is expected to be found on the shelves of leading dispensaries throughout Europe in the summer of 2022.
The strain of DNA flower were launched in the UK and co-branded with WeGROW in Lesotho. Initial interest has been strong and as anticipated. This new THC strain by WeGROW is collaborating on additional strains expected to be launched over the coming quarters.
In the Kingdom of Lesotho in Southern Africa, where the Company is growing multiple high THC premium strains as part of its trusted brands delivery strategy for international medical markets. WeGrow is growing these premium strains under ethical conditions and, over the coming quarters, plans to ramp production volumes from its grow campus situated in the heart of the country. This is to meet the demand for high-quality medical cannabis in rapidly growing international markets such as the U.K. and European Union, where the market is expected to reach $3.8 billion in annual sales by 2025 in Europe alone.
In addition, since WeGROW Lesotho achieved ‘Good Agricultural and Collection Practice’ (“GACP”) certification in August 2021 and is in active discussions with distributors to export these strains.
“Achiving this milestone of GACP certification together with the launch of the new strain reflects our comitment to deliver on our mission to bring unique and premium products to consumers in the EU, Middle East – and soon internationally,” commented Tal Arbeli, Director of WeGROW. “MikMik is a textbook showcase of the unique genetics perfected by our genetics team. Increasingly, WeGROW is recognized as an innovator and a premium brand house, and our exclusive access to these high-quality strains in Africa reinforces that differentiator.”
